ER2001 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses ER2001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- ER2001 injection
- 2
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
ExoRNA Bioscience (3)
Studies
Open first, then newest update. How each study uses ER2001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.CompletedEarly Phase 1ExoRNA BioscienceNCT07344519Written as ER2001 injection
- A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.Active, not recruitingPhase 1/2ExoRNA BioscienceNCT07339514Written as ER2001 intravenous injection
- The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's DiseaseCompletedEarly Phase 1ExoRNA BioscienceNCT06024265Written as ER2001 injection